Healthcare
Sunstone leads €8.7m Prexton Therapeutics round
Ysios Capital and MS Ventures also take part in series-A
VC-backed Heptares sold to Sosei for up to $400m
MVM, Clarus and Takeda make full exit from UK biotech
Kernel invests in Cirdan
Company already backed by development agency Invest NI
HTGF backs Immunservice’s series-C
GP previously injected seed capital in 2008
Gimv et al. sell ActoGenix for $60m
Transaction includes $30m worth of Intrexon stock
Mister Spex bolts on Lensit.no
VC-backed firm uses Goldman Sachs funding to finance deal
VC backers divest GlycoVaxyn to GSK
Deal values biopharmaceutical company at $212m
Albion exits Orchard Portman
Albion invested £8.4m in mental health hospital during tenure
VC-backed Bone Therapeutics raises €32m in IPO
Dual listing gives company a market cap of €104.8m
Smedvig leads $13.5m investment in TrialReach
Amadeus and Octopus also take part in round
Thuja et al. invest €1.8m in FabPulous
Thuja invested via its Thuja Capital Healthcare Fund
SHS backs AOT
Growing market for robot-guided surgical systems prompts investment
Thuja et al. invest €2.4m in Therasolve
VC was joined by business angels in the round
Kernel et al. invest €2m in Hibergene
Company will use the funds to commercialise its first two products
BMT backs Oncgnostics series-A
HTGF initially provided seed funding in 2012
Seventure’s AAA plans flotation
Company received €41m in funding last year
VC-backed Bone Therapeutics to list
Company could raise up to €28.8m at the top end of the indicative price range
Atlas Genetics raises $20m
Company will launch first testing product later this year
VC-backed Ascendis raises $108m in IPO
Listing priced at $18 per share
Industrifonden invests SEK 10m in AMRA
Second investment in company for Industrifonden
Caixa leads €1.6m round for Minoryx
VC's commitment drawn from €35m biotech fund
Yarpa and LBO France sell Izo to Vaxxinova
Italian animal vaccine business was acquired for a reported €15.2m in 2012
Capricorn et al. invest €1.3m in Feops
Funding will be used to launch company's first product in Europe and US
Fund in focus: Gilde Healthcare closes GHS II on €100m
Managing partner Jasper van Gorp shares details with unquote"